Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment in 2025
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > It’s going to take a longggggg time I bet
View:
Post by Dumbeldorfwhite on Nov 29, 2023 5:40am

It’s going to take a longggggg time I bet

To track down 25 people across two countries and convince them to come in for another exam, yikes. Why did the trial originally not plan for 18 month data is a question for the next AGM
Comment by Legit62 on Nov 29, 2023 6:54am
I dont believe that 18 month data has anything to do with us getting BTD or AA, dont know where that logic came from???
Comment by Longholder99 on Nov 29, 2023 7:03am
Soft but obvious bashers
Comment by Dumbeldorfwhite on Nov 29, 2023 7:51am
From my understanding they do, they want ~25 patients worth of data extending out to 18 months....could be clarified 
Comment by DJDawg on Nov 29, 2023 8:53am
I'm confused as to what you are describing. There is no tracking and convincing. 14 patients were CR at 15 months. Cancer patients don't say goodbye to their uro-oncologist at 15 m. There is routine follow up for years. Most importantly, you don't need anything more than to ask about the follow up cytologies. If the urine remains free of any cancer cells shedding AND they add a ...more  
Comment by N0taP00p on Nov 29, 2023 9:52am
@DJDawg, there's an additional step besides getting this data from the local PIs, isn't there?   After each center provides the data, they have to now validate it through a central lab. All this , when they're struggling to raise money.  If history repeats , we will be left with more questions than answers after the quarterly.   
Comment by N0taP00p on Nov 29, 2023 10:05am
And that's why I had mentioned Q1 "24 before as the earliest estimate for BTD.   Collection of data, validation of data, compile and submit for pre-BTD, wait for approval,  then compile and submit for BTD, wait for approval. All this, with limited money and the holidays in between.  
Comment by Oilminerdeluxe on Nov 29, 2023 10:39am
Most things take longer than expected with TLT. One just have to accept it.
Comment by Pandora on Nov 29, 2023 10:54am
I'll display my ignorance here. What is an aptimer relative to a vaccine? Are they completey separate paths of research? McMaster University working with a small company on an aptimer seems to have reached a significant level. Zentek is now looking for a partner to continue further. November 29, 2023 Zentek Ltd. (“Zentek” or the “Company”) (Nasdaq: ZTEK; TSX-V: ZEN), an intellectual ...more  
Comment by Eoganacht on Nov 29, 2023 11:50am
Hi Pandora - Google says: What is an Aptamer? The term “Aptamer” was coined by Andy Ellington. It stems from the Latin terms “aptus,” meaning to fit, and “meros,” meaning part. Aptamers are short, single-stranded DNA or RNA (ssDNA or ssRNA) molecules that can selectively bind to a specific target, including proteins, peptides, carbohydrates, small molecules, toxins, and ...more  
Comment by Pandora on Nov 29, 2023 11:57am
Thanks Eoganacht, I had looked at the Google definition but it does not answer my thinking. i.e. does this aptimer have any place in the development of a vaccine? Just wondering if the TLT vaccine group in Manitoba would get any use or benefit out of it. Clutching at straws I guess.
Comment by DJDawg on Nov 29, 2023 10:43am
Validating through a central lab is a complicated way of saying the following - pick one pathologist who is a bladder specialist (vs a generalist pathologist) - hire him - pull the 14 patient stored cytology and biopsy samples and mail them to the central pathologist to review and confirm as CR - most pathologists can review about 50-100 samples a day depending on tissue so quick on that part ...more  
Comment by Dumbeldorfwhite on Nov 29, 2023 10:44am
A few months for a company that barely has any cash
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed in 2025, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250